Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;23(5):514-516.
doi: 10.1016/S1473-3099(22)00828-3. Epub 2023 Jan 25.

Monoclonals against malaria: the promise of passive protection

Merel J Smit  1 , Matthew B B McCall  2
Affiliations
Comment

Monoclonals against malaria: the promise of passive protection

Merel J Smit et al. Lancet Infect Dis. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

  • Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
    Lyke KE, Berry AA, Mason K, Idris AH, O'Callahan M, Happe M, Strom L, Berkowitz NM, Guech M, Hu Z, Castro M, Basappa M, Wang L, Low K, Holman LA, Mendoza F, Gordon IJ, Plummer SH, Trofymenko O, Strauss KS, Joshi S, Shrestha B, Adams M, Chagas AC, Murphy JR, Stein J, Hickman S, McDougal A, Lin B, Narpala SR, Vazquez S, Serebryannyy L, McDermott A, Gaudinski MR, Capparelli EV, Coates EE, Wu RL, Ledgerwood JE, Dropulic LK, Seder RA; VRC 612 Part C Study Team. Lyke KE, et al. Lancet Infect Dis. 2023 May;23(5):578-588. doi: 10.1016/S1473-3099(22)00793-9. Epub 2023 Jan 25. Lancet Infect Dis. 2023. PMID: 36708738 Free PMC article. Clinical Trial.

Substances

LinkOut - more resources